Nordea Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.03M | Buy |
26,913
+13,567
| +102% | +$4.09M | 0.01% | 498 |
|
|
2026
Q1 | $4.35M | Buy |
13,346
+491
| +4% | +$167K | ﹤0.01% | 617 |
|
|
2025
Q4 | $5.12M | Buy |
12,855
+374
| +3% | +$166K | ﹤0.01% | 583 |
|
|
2025
Q3 | $5.65M | Buy |
12,481
+1,186
| +11% | +$483K | ﹤0.01% | 566 |
|
|
2025
Q2 | $3.64M | Buy |
11,295
+1,060
| +10% | +$293K | ﹤0.01% | 621 |
|
|
2025
Q1 | $2.71M | Buy |
10,235
+47
| +0.5% | +$12.1K | ﹤0.01% | 646 |
|
|
2024
Q4 | $2.42M | Buy |
10,188
+637
| +7% | +$168K | ﹤0.01% | 657 |
|
|
2024
Q3 | $2.63M | Buy |
9,551
+117
| +1% | +$30.5K | ﹤0.01% | 645 |
|
|
2024
Q2 | $2.31M | Buy |
9,434
+454
| +5% | +$71.7K | ﹤0.01% | 677 |
|
|
2024
Q1 | $1.37M | Buy |
8,980
+290
| +3% | +$48.4K | ﹤0.01% | 773 |
|
|
2023
Q4 | $1.67M | Hold |
8,690
| – | – | ﹤0.01% | 736 |
|
|
2023
Q3 | $1.53M | Buy |
8,690
+263
| +3% | +$50.2K | ﹤0.01% | 746 |
|
|
2023
Q2 | $1.65M | Sell |
8,427
-216
| -2% | -$42.8K | ﹤0.01% | 731 |
|
|
2023
Q1 | $1.71M | Buy |
8,643
+96
| +1% | +$20.2K | ﹤0.01% | 704 |
|
|
2022
Q4 | $2.02M | Buy |
8,547
+1,293
| +18% | +$276K | ﹤0.01% | 671 |
|
|
2022
Q3 | $1.57M | Buy |
7,254
+104
| +1% | +$19.8K | ﹤0.01% | 712 |
|
|
2022
Q2 | $1.03M | Buy |
7,150
+272
| +4% | +$38.6K | ﹤0.01% | 785 |
|
|
2022
Q1 | $1.15M | Sell |
6,878
-268
| -4% | -$40.8K | ﹤0.01% | 779 |
|
|
2021
Q4 | $1.25M | Buy |
7,146
+1,994
| +39% | +$371K | ﹤0.01% | 771 |
|
|
2021
Q3 | $946K | Hold |
5,152
| – | – | ﹤0.01% | 818 |
|
|
2021
Q2 | $873K | Hold |
5,152
| – | – | ﹤0.01% | 828 |
|
|
2021
Q1 | $725K | Sell |
5,152
-270
| -5% | -$40.6K | ﹤0.01% | 834 |
|
|
2020
Q4 | $705K | Hold |
5,422
| – | – | ﹤0.01% | 810 |
|
|
2020
Q3 | $782K | Sell |
5,422
-5,422
| -50% | -$771K | ﹤0.01% | 752 |
|
|
2020
Q2 | $1.61M | Buy |
10,844
+6,079
| +128% | +$820K | ﹤0.01% | 742 |
|
|
2020
Q1 | $523K | Hold |
4,765
| – | – | ﹤0.01% | 790 |
|
|
2019
Q4 | $549K | Buy |
4,765
+1,314
| +38% | +$131K | ﹤0.01% | 834 |
|
|
2019
Q3 | $281K | Buy |
3,451
+465
| +16% | +$36.8K | ﹤0.01% | 920 |
|
|
2019
Q2 | $217K | Hold |
2,986
| – | – | ﹤0.01% | 952 |
|
|
2019
Q1 | $279K | Hold |
2,986
| – | – | ﹤0.01% | 1137 |
|
|
2018
Q4 | $218K | Hold |
2,986
| – | – | ﹤0.01% | 1143 |
|
|
2018
Q3 | $261K | Hold |
2,986
| – | – | ﹤0.01% | 1192 |
|
|
2018
Q2 | $294K | Hold |
2,986
| – | – | ﹤0.01% | 981 |
|
|
2018
Q1 | $356K | Hold |
2,986
| – | – | ﹤0.01% | 996 |
|
|
2017
Q4 | $379K | Buy |
+2,986
| New | +$375K | ﹤0.01% | 930 |
|
|
2016
Q4 | – | Sell |
-2,105
| Closed | -$143K | – | 1038 |
|
|
2016
Q3 | $143K | Hold |
2,105
| – | – | ﹤0.01% | 963 |
|
|
2016
Q2 | $117K | Hold |
2,105
| – | – | ﹤0.01% | 940 |
|
|
2016
Q1 | $132K | Buy |
2,105
+184
| +10% | +$12.2K | ﹤0.01% | 880 |
|
|
2015
Q4 | $181K | Hold |
1,921
| – | – | ﹤0.01% | 761 |
|
|
2015
Q3 | $154K | Hold |
1,921
| – | – | ﹤0.01% | 753 |
|
|
2015
Q2 | $230K | Buy |
+1,921
| New | +$230K | ﹤0.01% | 708 |
|
Other funds holding ALNY
Nordea Investment Management's ALNY Position: Q2 2026 in Review
Nordea Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 102% in Q2 2026, buying an estimated $4.09M and bringing the position to 26,913 shares worth $8.03M. The position accounts for 0.01% of the portfolio, ranked #498.
Nordea Investment Management first reported a position in ALNY in Q2 2015 and has held it in 41 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Nordea Investment Management held 26,913 shares of Alnylam Pharmaceuticals worth $8.03M as of Q2 2026.
- Nordea Investment Management bought 13,567 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.09M.
- Alnylam Pharmaceuticals made up 0.01% of Nordea Investment Management's portfolio in Q2 2026, its #498 holding.
- Nordea Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.